UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 喘息におけるβ刺激剤：長期使用に関する議論 beta agonists in asthma controversy regarding chronic use
2. 喘息のマネージメントの概要 an overview of asthma management
3. 青年や成人の中等度持続型喘息の治療 treatment of moderate persistent asthma in adolescents and adults
4. 青年や成人の間欠型喘息および軽症持続型喘息の治療 treatment of intermittent and mild persistent asthma in adolescents and adults
5. 青年や成人の重症喘息の治療 treatment of severe asthma in adolescents and adults

English Journal

Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy.

Cossette B1, Beauchesne MF2, Forget A3, Lemière C4, Larivée P5, Rey E6, Blais L7.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.Ann Allergy Asthma Immunol.2014 May;112(5):459-64. doi: 10.1016/j.anai.2014.02.010. Epub 2014 Mar 19.
BACKGROUND: Recent asthma guidelines endorse the safety of long-acting β2-agonists (LABAs) and of mild and moderate doses of inhaled corticosteroids (ICSs) when required to control asthma during pregnancy, yet do not state a preferred medication within each class.OBJECTIVE: To estimate the relative
PMID 24656659

Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease.

Matera MG1, Rogliani P, Cazzola M.
Expert opinion on pharmacotherapy.Expert Opin Pharmacother.2014 May;15(7):961-77. doi: 10.1517/14656566.2014.899581. Epub 2014 Mar 26.
Introduction: Long-acting muscarinic receptor antagonists (LAMAs) are central to the treatment of chronic obstructive pulmonary disease (COPD) because of the important role of the cholinergic system in the pathophysiology of this disorder. Areas covered: LAMAs show clinically meaningful effects in l
PMID 24669979

Development of a mouse model mimicking key aspects of a viral asthma exacerbation.

Clarke DL, Davis NH, Majithiya JB, Piper SC, Lewis A, Sleeman MA, Corkill DJ, May RD.
Clinical science (London, England : 1979).Clin Sci (Lond).2014 Apr;126(8):567-80. doi: 10.1042/CS20130149.
Viral respiratory tract infections are known triggers of asthma exacerbations in both adults and children. The current standard of care, inhaled CS (corticosteroids) and LABAs (long-acting β2-adrenoceptor agonists), fails to prevent the loss of control that manifests as an exacerbation. In order to
PMID 24152048